Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Peter A. Prieto, M.D., M.P.H.

Contact Information

Phone Numbers

Appointment: (585) 275-1611

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Research Labs

Faculty Appointments

Patient Care Setting



Professional Background

A native of New York, Dr. Peter A. Prieto chose to dedicate his life to conquering cancer after losing his father to sarcoma. Dr. Prieto, completed his general surgery residency at Yale University School of Medicine where he took three years off and completed a surgical oncology research fellowship and a one of its kind immunotherapy fellowship in the surgery branch of the National Cancer Institute, National Institutes of Health under the mentorship of Dr. Steven A. Rosenberg where he was co-investigator on numerous clinical trials.

He went on to complete his chief residency at Yale and then completed a two year clinical complex surgical oncology fellowship at the prestigious and consistently ranked #1 Cancer Center in the United States, University of Texas MD Anderson Cancer Center in Houston, Texas where he spent an additional year doing a post-doctoral research fellowship under the mentorship of Drs. Jennifer A. Wargo and Funda Meric-Bernstam. At MD Anderson Dr. Prieto was instrumental in the development and analysis of a novel phase II trial looking at neoadjuvant targeted therapy in high-risk resectable stage III BRAF mutant melanoma, which has changed the practice in this challenging patient population.

Dr. Prieto is triple board certified in complex general surgical oncology, general surgery and medical quality. As a fully trained tumor immunotherapist and surgical oncologist, he has expertise in the treatment of primary, regionally advanced and metastatic melanoma, soft tissue sarcoma and breast cancer. His research interests and laboratory investigate mechanisms of immune evasion by solid tumors to targeted and immune checkpoint blockade and prognostic markers of response to immune based therapies including adoptive cell therapy (including melanoma, sarcoma, cholangiocarcinoma and breast cancer).

Dr. Prieto serves on the Society of Surgical Oncology's Sarcoma Disease Site Workgroup Committee and is the Cancer Center Physician Liason to the American College of Surgeons Committee on Cancer.

In addition to authoring numerous high impact publications, Dr. Prieto is the recipient of several prestigious awards and honors. He frequently presents on topics related to surgical oncology and melanoma at the national and international levels. Dr. Prieto's personal mission is to treat all of his patients as if they were his own family.



  • Complex General Surgical Oncology
  • Surgery - American Board of Surgery


MD, MPH | St. George's University School of Medicine

Post-doctoral Training & Residency

07/01/2014 - 6/30/2017
Fellowship in Complex General Surgical Oncology at University of Texas M D Anderson Cancer Center

07/01/2011 - 06/30/2014
Residency in General Surgery at Yale New Haven Hospital

07/01/2009 - 6/30/2011
Fellowship in Surgical Oncology at National Cancer Institute

07/01/2008 - 06/30/2009
Fellowship in Immunotherapy at National Cancer Institute

07/01/2007 - 06/30/2008
Residency in General Surgery at State University of New York, Upstate Medical University

07/01/2006 - 06/30/2007
Internship in General Surgery at State University of New York, Upstate Medical University

VIEW ALL expand_more


Seymour I. Schwartz Faculty Excellence in Teaching
Sponsor: University of Rochester School of Medicine and Dentistry

2017 - 2018
W. G. Stuber Research Fellowship Grant
Sponsor: University of Rochester Medical Center

Lotzova Excellence in Research Award, Department of Surgical Oncology
Sponsor: University of Texas MD Anderson Cancer Center

Lotzova Excellence in Research Award, Department of Surgical Oncology
Sponsor: University of Texas MD Anderson Cancer Center

Excellence in Junior Resident Teaching Award
Sponsor: Yale School of Medicine

Sam Harvey Award for Most Outstanding Chief Resident in Surgery
Sponsor: Yale School of Medicine

Excellence In Medical Student Teaching Award
Sponsor: Yale School of Medicine

Arnold P. Gold Humanism Honor Society
Sponsor: St. George's University

Research Career for Minority Scholars (RCMS)
Sponsor: SUNY at Stony Brook

VIEW ALL expand_more


Journal Articles

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, , Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. "Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium." The Lancet. Oncology.. 2019 Jul 0; 20(7):e378-e389.

Patel AP, Peacock JL, Prieto PA. "High-grade angiosarcoma presenting with cytology-negative hemorrhagic ascites." Journal of surgical case reports.. 2018 Oct 0; 2018(10):rjy273. Epub 2018 Oct 11.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial." The Lancet. Oncology.. 2018 Feb 0; 19(2):181-193. Epub 2018 Jan 18.